Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

by · The Cerbat Gem

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) insider Beth Hecht sold 16,667 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $7.01, for a total transaction of $116,835.67. Following the transaction, the insider owned 1,320,176 shares of the company’s stock, valued at $9,254,433.76. This represents a 1.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Beth Hecht also recently made the following trade(s):

  • On Tuesday, November 11th, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $7.40, for a total transaction of $123,335.80.

Xeris Biopharma Trading Down 7.0%

Xeris Biopharma stock traded down $0.49 during midday trading on Tuesday, reaching $6.47. 3,144,537 shares of the stock traded hands, compared to its average volume of 2,499,296. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $3.14 and a fifty-two week high of $10.08. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -64.69 and a beta of 0.58. The firm has a fifty day moving average price of $8.21 and a two-hundred day moving average price of $6.69.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.00 EPS for the quarter, missing the consensus estimate of $0.01 by ($0.01). The business had revenue of $74.38 million for the quarter, compared to the consensus estimate of $74.19 million. Analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Wall Street Analyst Weigh In

XERS has been the topic of several recent analyst reports. Leerink Partners lifted their target price on Xeris Biopharma from $7.00 to $9.00 and gave the company an “outperform” rating in a research note on Tuesday, August 19th. Oppenheimer restated an “outperform” rating and set a $18.00 price objective on shares of Xeris Biopharma in a research note on Friday, November 7th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a report on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, October 8th. Finally, Zacks Research downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 30th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.58.

Get Our Latest Stock Analysis on Xeris Biopharma

Institutional Investors Weigh In On Xeris Biopharma

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Nuveen LLC acquired a new stake in Xeris Biopharma in the 1st quarter valued at about $12,240,000. UBS Group AG raised its holdings in shares of Xeris Biopharma by 682.4% in the 3rd quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock worth $14,511,000 after purchasing an additional 1,554,869 shares in the last quarter. Qube Research & Technologies Ltd raised its holdings in shares of Xeris Biopharma by 67.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock worth $14,429,000 after purchasing an additional 1,245,188 shares in the last quarter. Parkman Healthcare Partners LLC lifted its stake in Xeris Biopharma by 207.8% during the first quarter. Parkman Healthcare Partners LLC now owns 1,780,454 shares of the company’s stock valued at $9,775,000 after purchasing an additional 1,201,943 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after buying an additional 1,199,435 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors.

Xeris Biopharma Company Profile

(Get Free Report)

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Recommended Stories